Analyst John Newman from Canaccord Genuity maintained a Buy rating on Adicet Bio (ACET – Research Report) and keeping the price target at $8.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
John Newman has given his Buy rating due to a combination of factors including Adicet Bio’s promising pipeline and strategic developments. The company is advancing its ADI-001 and ADI-270 programs, with expected data readouts in the second half of 2025, which are anticipated to provide significant insights into their efficacy in treating conditions like Lupus Nephritis and Renal Cell Carcinoma.
Additionally, Adicet Bio is expanding its focus by enrolling patients for Systemic Lupus Erythematosus and introducing new programs targeting autoimmune diseases and metastatic castration-resistant prostate cancer. These strategic initiatives, coupled with the company’s innovative use of gamma delta T-cells, which may offer superior tissue penetration and efficacy, underpin Newman’s positive outlook. Furthermore, the company’s financial position, with a cash runway extending into the second half of 2026, supports the continued development of its pipeline, reinforcing the Buy rating with a price target of $8.